Courtney Cupples is the Chief Commercial Officer at Abcuro and brings more than 25 years of global experience in commercializing orphan drug medicines for rare diseases. Prior to joining Abcuro, Courtney served as Chief Commercial Officer for Priovant Therapeutics, where she led commercial launch preparation for the company’s oral small molecule, brepocitinib, currently in development for the potential treatment of severe autoimmune diseases. Prior to this, Courtney spent five years at Biohaven Pharmaceuticals where she led commercial strategic planning for the company’s clinical-stage rare disease portfolio focused primarily on neuromuscular conditions. Before Biohaven, she spent nine years at Alexion Pharmaceuticals where she led the launch of Soliris®(eculizumab) in Latin America, served as leader of the global franchise for the atypical hemolytic uremic syndrome (aHUS) indication for (Soliris®) and led the global metabolic disease franchise for Strensiq®(asfotase alfa) and Kanuma®(sebelipase alfa). Courtney began her career at Genzyme Corporation where she served in various commercial roles over 11 years, driving expansion of the company’s enzyme replacement therapy business in Latin America. Courtney holds a Bachelor of Arts in Sociology & Anthropology from Swarthmore College.
Cupples, Courtney
Courtney Cupples
Chief Commercial Officer
x
Courtney Cupples
Chief Commercial Officer
Courtney Cupples is the Chief Commercial Officer at Abcuro and brings more than 25 years of global experience in commercializing orphan drug medicines for rare diseases. Prior to joining Abcuro, Courtney served as Chief Commercial Officer for Priovant Therapeutics, where she led commercial launch preparation for the company’s oral small molecule, brepocitinib, currently in development for the potential treatment of severe autoimmune diseases. Prior to this, Courtney spent five years at Biohaven Pharmaceuticals where she led commercial strategic planning for the company’s clinical-stage rare disease portfolio focused primarily on neuromuscular conditions. Before Biohaven, she spent nine years at Alexion Pharmaceuticals where she led the launch of Soliris®(eculizumab) in Latin America, served as leader of the global franchise for the atypical hemolytic uremic syndrome (aHUS) indication for (Soliris®) and led the global metabolic disease franchise for Strensiq®(asfotase alfa) and Kanuma®(sebelipase alfa). Courtney began her career at Genzyme Corporation where she served in various commercial roles over 11 years, driving expansion of the company’s enzyme replacement therapy business in Latin America. Courtney holds a Bachelor of Arts in Sociology & Anthropology from Swarthmore College.
